Integral Derivatives’s TG Therapeutics TGTX Stock Holding History

Integral Derivatives’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,975	Closed	-$56K	–	1363
2016 Q4	$56K	Buy	+11,975	New	+$70.2K	﹤0.01%	1086

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Derivatives's TGTX Position: Q1 2017 in Review

Integral Derivatives sold out of TG Therapeutics (TGTX) in Q1 2017, closing a stake of 11,975 shares — an estimated $56K sold.

Integral Derivatives first reported a position in TGTX in Q4 2016 and held it in 1 quarter. The position peaked at $56K in Q4 2016. 97 funds tracked by Wall St. Rank hold TGTX as of Q1 2017.

Integral Derivatives reported no remaining TG Therapeutics position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 11,975 TG Therapeutics shares in Q1 2017, an estimated $56K.
Integral Derivatives first reported a position in TG Therapeutics in Q4 2016 and held it in 1 quarter.
Integral Derivatives's TG Therapeutics position peaked at $56K in Q4 2016.
97 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.